natgillin/translations-raw huggingface dataset:
Prophylactic or empiric use of anti-infectives (bacterial, fungal, viral) should be considered for the prevention and management of infections during the neutropenic period. 
Za preprečevanje in nadzorovanje okužb tekom nevtropeničnega obdobja, je priporočljiva preventivna ali empirična uporaba zdravil proti okužbam (bakterijskim, glivičnim in virusnim).
Busulfan will be administered every 6 hours during 4 consecutive days prior to transplant. 
- Zdravilo Busulfan Fresenius Kabi boste prejemali na vsakih 6 ur, 4 dni zaporedoma pred presaditvijo.
The most frequent causes of reported TRM/NRMs were infection/sepsis, GVHD, pulmonary disorders and organ failure. 
Najpogostejši vzroki zabeleženih ZPU/UNP so bili okužba/sepsa, bolezen presadka proti gostitelju, pljučne bolezni in odpovedi organov.
Busulfan Fresenius Kabi is supplied as a clear colourless viscous solution in 10 ml clear, colourless glass vials (type I). 
Zdravilo Busulfan Fresenius Kabi je na voljo kot bistra, brezbarvna, viskozna raztopina v prozornih, brezbarvnih, steklenih vialah (steklo tipa I) s prostornino 10 ml.
Other frequent anomalies included cleft palate, anasarca and skeletal anomalies of the vertebrae and ribs. 
Med preostale pogoste anomalije sodi volčje žrelo, ansarka in anomalije vretenc ter reber.
Since, busulfan is metabolized through conjugation with glutathione, administration of glutathione might be considered. 
Ker pa se busulfan presnavlja s konjugacijo z glutationom, je smiselno uporabiti tudi glutation.
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109 /l was 13 days (range 9-29 days) in allogenic patients (OMC-BUS 4), and 10 days (range 8-19 days) in autologous patients (OMC-BUS 3). 
Čas za dosego absolutnega števila nevtrofilcev, večjega od 0,5 x 109/l , je bil pri alogenskih bolnikih (OMC-BUS-4) 13 dni (v razponu 9-29 dni), pri avtolognih bolnikih (OMC-BUS-3) pa 10 dni (v razponu 8-19 dni).
Busulfan followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option. 
Postopek z busulfanom in nato s ciklofosfamidom (BuCy2) se uporablja kot pripravljalna terapija pred transplantacijo hematopoetskih progenitorskih celic (HPCT - Haematopoietic Progenitor Cell Transplantation) pri odraslih bolnikih, kadar ocenimo, da je ta kombinacija najboljša možnost.
In adults, absolute neutrophil counts < 0.5x109/l at a median of 4 days post transplant occurred in 100% of patients and recovered at median day 10 and 13 days following autologous and allogeneic transplant respectively (median neutropenic period of 6 and 9 days respectively). 
Pri odraslih se je absolutno število nevtrofilcev < 0,5 x 109/l mediano 4 dni po transplantaciji pojavilo pri 100 % bolnikov in se je popravilo mediano 10 dni po avtologni oziroma 13 dni po alogenski transplantaciji (mediano trajanje nevtropenije je znašalo 6 oziroma 9 dni).
In new-born infants, children and adolescents, this medicine is used in combination with cyclophosphamide or melphalan. 
Pri novorojenčkih, otrocih in mladostnikih se zdravilo Busulfan Fresenius Kabi uporablja v kombinaciji s ciklofosfamidom ali z melfalanom.
Two prospective, single arm, open-label, uncontrolled phase II studies were conducted in patients with haematological disease, the majority of whom had advanced disease. 
V drugi klinični fazi sta bili na bolnikih s hematološkimi obolenji, pri večini katerih je bolezen že napredovala, opravljeni dve eno-kraki, odprti, nekontrolirani raziskavi možnosti zdravljenja.
Therefore it is advised not to father child during the treatment and up to 6 months after treatment and to seek advice on cryo-conservation of sperm prior to treatment because of the possibility of irreversible infertility (see section 4.4). 
Priporočamo, da se pred zdravljenjem posvetujejo o shranitvi semena z zamrznitvijo, ker zaradi zdravljenja obstaja možnost trajne neplodnosti (glejte poglavje 4.4).
Busulfan treatment in a pre-adolescent girl prevented the onset of puberty due to ovarian failure. 
Zdravljenje z busulfanom je pri dekletu pred adolescenco zaradi okvare jajčnikov preprečilo začetek pubertete.
- the calculated volume of Busulfan Fresenius Kabi must be removed from the vial. 
- izračunan volumen zdravila Busulfan Fresenius Kabi morate odstraniti iz viale,
In adults and children studies, data with busulfan were obtained when using concomitant administration of either phenytoin or benzodiazepines for seizure prophylaxis. 
Vsi podatki o busulfanu v študijah pri odraslih in otrocih so bili pridobljeni pri sočasni uporabi fenitoina ali benzodiazepinov, kot profilakso pred epileptičnimi napadi.
What Busulfan Fresenius Kabi contains - The active substance is busulfan. 
Kaj vsebuje zdravilo Busulfan Fresenius Kabi - Zdravilna učinkovina je busulfan.
Uncommon (may affect up to 1 in 100 people): 
Občasni (pojavijo se lahko pri največ 1 od 100):
Men treated with Busulfan Fresenius Kabi are advised not to father child during and up to 6 months after treatment. 
Moškim, ki prejemajo zdravilo Busulfan Fresenius Kabi, svetujemo, naj ne zaplodijo otroka med zdravljenjem in še vsaj 6 mesecev po zdravljenju.
What Busulfan Fresenius Kabi looks like and contents of the pack Busulfan Fresenius Kabi consists of a concentrate for solution for infusion. 
Izgled zdravila Busulfan Fresenius Kabi in vsebina pakiranja Zdravilo Busulfan Fresenius Kabi je koncentrat za raztopino za infundiranje.
Published studies in adults described that ketobemidone (analgesic) might be associated with high levels of plasma busulfan. 
Objavljene raziskave, opravljene na odraslih bolnikih, opisujejo možnost povezave med ketobemidonom, (analgetik) in visokimi plazemskimi koncentracijami busulfana.
Busulfan followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients. 
Postopek z busulfanom in nato s ciklofosfamidom (BuCy4) ali melfalanom (BuMel) se uporablja kot pripravljalna terapija pred transplantacijo hematopoetskih progenitorskih celic pri pediatričnih bolnikih.
The successful engraftment achieved in all patients during phase II trials suggests the appropriateness of the targeted AUCs. 
Uspešna presaditev pri vseh bolnikih v preskušanjih II.
Prior to and following each infusion, flush the indwelling catheter line with approximately 5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection or glucose (5%) solution for injection. 
Pred in po vsaki infuziji izperite katetrsko cev s približno 5 ml 0,9 % raztopine natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopine glukoze za injiciranje.
Nervous system: delirium, nervousness, hallucination, agitation, abnormal brain function, cerebral haemorrhage, and seizure. 
Živčni sistem: delirij, nervoza, prividi, nemirnost, nenormalno delovanje možganov, možganske krvavitve in epileptični napadi.
Respiratory: increase in breath rhythm, respiratory failure, alveolar haemorrhages, asthma, collapse of small portions of the lung, fluid around the lung. 
Dihala: povečana frekvenca dihanja, dihalna odpoved, alveolarne krvavitve, astma, ohlapnost manjših delov pljuč, nabiranje tekočine okrog pljuč.
What Busulfan Fresenius Kabi is and what it is used for 
Kaj je zdravilo Busulfan Fresenius Kabi in za kaj ga uporabljamo 2.
Increase of uric acid and urea in the blood. 
Povišanje sečne kisline in sečnine v krvi.
Busulfan Fresenius Kabi in combination with cyclophosphamide: - The recommended dose of Busulfan Fresenius Kabi is 0.8 mg/kg 
Zdravilo Busulfan Fresenius Kabi v kombinaciji s ciklofosfamidom - Priporočeni odmerek zdravila Busulfan Fresenius Kabi je 0,8 mg/kg.
Women must not be pregnant during treatment with Busulfan Fresenius Kabi and up to 6 months after treatment. 
Ženske, ki prejemajo zdravilo Busulfan Fresenius Kabi, ne smejo biti noseče med zdravljenjem in ne smejo zanositi še do 6 mesecev po zdravljenju.
However cardiac function should be monitored regularly in patients receiving busulfan (see section 4.8). 
Vendar je pri bolnikih, ki so prejemali busulfan, potreben reden nadzor delovanja srca (glejte poglavje 4.8).
Cardiac: increase in heart rate, increase or decrease of blood pressure, vasodilatation (a state of increased calibre of the blood vessels), and blood clots. 
Srce: povišan srčni utrip, dvig ali padec krvnega tlaka, vazodilatacija (razširjenje krvnih žil) in krvni strdki.
Lens disorders including clouding of the lens of the eye (cataract), and blurred vision (corneal thinning) 
Bolezni očesne leče, vključno s sivo mreno (katarakta) in motnjami vida (tanjšanje roženice).
The effect of those anticonvulsant agents on busulfan pharmacokinetics was investigated in a phase II study (see section 4.5). 
Učinek teh protikonvulzivnih učinkovin na farmakokinetiko busulfana so raziskovali v študiji II.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 60 mg/10 ml OTHER Cytotoxic 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 60 mg/10 ml
Hyperglycaemia Hypocalcaemia Hypokalaemia Hypomagnesaemia Hypophosphatemia 
Presnovne in prehranske motnje anoreksija hiperglikemija hipokalcemija hipokaliemija hipomagneziemija hipofosfatemija hiponatriemija
CARTON containing 1 vial 
PODATKI NA PRIMARNI OVOJNINI KARTON, ki vsebuje 1 vialo
LIST OF EXCIPIENTS Excipients: Dimethylacetamide and Macrogol 400 
SEZNAM POMOŽNIH SNOVI Pomožne snovi: dimetilacetamid in makrogol 400.
** reported in post marketing with IV busulfan *** reported in post marketing with oral busulfan 
** objavljeno v obdobju, ko je zdravilo že na trgu, pri intravenskem dajanju busulfana *** objavljeno v obdobju, ko je zdravilo že na trgu, pri peroralnem jemanju busulfana
What you need to know before you use Busulfan Fresenius Kabi 
Kaj morate vedeti, preden boste uporabili zdravilo Busulfan Fresenius Kabi
Platelet and red blood cell support, as well as the use of growth factors such as granulocyte colony stimulating agent (G-CSF), should be employed as medically indicated. 
V primeru zdravstvenih indikacij je potrebno nuditi trombocitno ali eritrocitno podporo in uporabiti rastne faktorje, kot je granulocitne kolonije stimulirajoči faktor (G-CSF).
One patient experienced a fatal case of acute respiratory distress syndrome with subsequent respiratory failure associated with interstitial pulmonary fibrosis in the busulfan studies. 
Pri raziskavah busulfana je bil pojav akutnega sindroma dihalne stiske s posledično respiratorno odpovedjo, povezano z intersticijsko fibrozo pljuč, pri enem bolniku smrten.
The dose proportional increase of busulfan exposure was demonstrated following intravenous busulfan up to 1 mg/kg. 
Po intravenski uporabi busulfana v odmerkih do 1 mg/kg so dokazali, da je izpostavljenost busulfanu naraščala sorazmerno z odmerkom.
• Busulfan Fresenius Kabi must be prepared by a healthcare professional using sterile transfer techniques. 
• Zdravilo Busulfan Fresenius Kabi mora pripraviti usposobljen zdravstveni delavec/delavka v sterilnih pogojih.
Busulfan Fresenius Kabi must always be added to the diluent, not the diluent to the Busulfan Fresenius Kabi. 
Zdravilo Busulfan Fresenius Kabi morate vedno dodajati v redčilo in ne redčila v zdravilo Busulfan Fresenius Kabi.
Occurrence of acute respiratory distress syndrome with subsequent respiratory failure associated with interstitial pulmonary fibrosis was reported in busulfan studies in one patient who died, although, no clear aetiology was identified. 
V raziskavah busulfana je bil pri enem bolniku, ki je umrl, zabeležen pojav sindroma akutne dihalne stiske, ki ji je sledila respiratorna odpoved, povezana z intersticijsko pljučno fibrozo, vendar jasne etiologije niso identificirali.
The effects of renal dysfunction on intravenous busulfan disposition have not been assessed. 
Učinki okvare ledvic na delovanje intravensko uporabljenega busulfana še niso bili ocenjeni.
Clear, colourless viscous solution. 
Bistra, brezbarvna, viskozna raztopina.
Low inter (CV=21%) and intra (CV=12%) patient variability on busulfan exposure was demonstrated through a population pharmacokinetic analysis, performed on 102 patients. 
Med farmakokinetično analizo, izvedeno pri 102 bolnikih, so znotraj populacije ugotovili nizko inter- (CV = 21 %) in intravariabilnost (CV = 12 %) bolnikov pri izpostavitvi busulfanu.
Respiratory: shortness of breath, nasal secretion (rhinitis), sore throat, cough, hiccup, nosebleeds, abnormal breath sounds. 
Dihala: kratka sapa, izcedek iz nosu (rinitis), vneto grlo, kašelj, kolcanje, krvavitve iz nosu, neobičajni zvoki pri dihanju.
No evidence of an induction effect of phenytoin has been seen on busulfan data. 
V podatkih o busulfanu ni bilo dokazov za indukcijski učinek fenitoina.
General: fever, headache, weakness, chills, pain, allergic reaction, oedema, general pain or inflammation at injection site, chest pain, inflammation of the mucosa. 
Splošno: povišana telesna temperatura, glavobol, oslabelost, mrzlica, bolečina, alergijske reakcije, edem, bolečina ali vnetje na mestu vboda, bolečina v prsih, vnetje sluznic.
Haematuria Moderate renal insufficiency 
Bolezni sečil disurija oligurija hematurija zmerna ledvična insuficienca
Similar blood exposure was observed when comparing plasma concentrations in adult patients receiving oral and intravenous busulfan at 1 mg/kg and 0.8 mg/kg respectively. 
Med primerjavo plazemskih koncentracij po peroralni in intravenski uporabi busulfana, pri odraslih bolnikih (odmerek 1 mg/kg in 0,8 mg/kg) so opazili podobno prisotnost učinkovine v krvi.
Platelet engraftment occurred at a median of 9 (range, 1-16) days after allo-HCT. 
Vsaditev trombocitov se je pojavila mediano 9 dni (razpon: od 1 do 16) po homologni transplantaciji hematopoetskih celic.
In children, thrombocytopenia (< 25x109/l or requiring platelet transfusion) occurred in 100% of patients. 
Trombocitopenija (< 25 x 109/l ali zahtevana transfuzija trombocitov) se je pojavila pri 100 % bolnikov.
Arrhythmia Atrial fibrillation Cardiomegaly Pericardial effusion 
Srčne bolezni tahikardija aritmija atrijska fibrilacija kardiomegalija perikardialni ventrikularna ekstrasistola bradikardija
Delirium Nervousness Hallucination Agitation 
Psihiatrične motnje tesnoba depresija nespečnost zmedenost delirij živčnost halucinacije vznemirjenost
The use of paracetamol during the 72 hours prior to or with Busulfan Fresenius Kabi administration should be used with caution. 
Bodite zelo previdni pri uporabi paracetamola 72 ur pred uporabo ali sočasno z uporabo zdravila Busulfan Fresenius Kabi.
To prepare the final solution for infusion, add (A) ml of Busulfan Fresenius Kabi to (B) ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%) 
Za pripravo končne raztopine za infundiranje dodajte (A) ml zdravila Busulfan Fresenius Kabi v (B) ml redčila (0,9 % raztopina natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopina glukoze za injiciranje).
Dimethylacetamide Macrogol 400 
6.1 Seznam pomožnih snovi dimetilacetamid makrogol 400
A final concentration of approximately 0.5 mg/ml busulfan should be achieved. 
Tako zagotovimo končno koncentracijo busulfana približno 0,5 mg/ml.
A continuous variation of clearance ranging from 2.49 to 3.92 ml/minute/kg has been established in children from < 6 months up to 17 years old. 
Pri otrocih, starih manj od 6 mesecev do 17 let, so ugotovili stalno nihanje očistka v intervalu med 2,49 in 3,92 ml/min/kg.
Busulfan depleted oocytes of female rats, and induced sterility in male rats and hamster. 
Busulfan je pri samicah podgan uničil oocite; pri samcih podgan in hrčkov pa je povzročil neplodnost.
After dilution: one ml of solution contains approximately 0.5 mg of busulfan. 
Po redčenju: 1 ml raztopine vsebuje približno 0,5 mg busulfana.
There is limited clinical experience of the use of busulfan as a component of a conditioning regimen prior to HSCT in children with Fanconi's anaemia. 
Ni zadostnih kliničnih izkušenj z uporabo busulfana kot komponente pri pripravljalnem zdravljenju pred presajanjem hematopoetskih matičnih celic (HSCT), pri otrocih s Fanconijevo anemijo, zato je treba busulfan pri tej skupini bolnikov uporabljati previdno.
The effects of hepatic dysfunction on intravenous busulfan disposition have not been assessed. 
Učinki okvare jeter na delovanje intravensko uporabljenega busulfana še niso bili ocenjeni.
Hepatic: enlarged liver, jaundice, blocking of a liver vein. 
Jetra: povečanje jeter, zlatenica, zaprtje jetrne vene.
Either phenytoin or benzodiazepines were administered for seizure prophylaxis in patients participating to the clinical trials conducted with intravenous busulfan (see section 4.2 and 4.4). 
Pri bolnikih, ki so sodelovali v kliničnih preskušanjih z intravensko uporabo busulfana, so za preprečevanje epileptičnih napadov uporabili fenitoin ali benzodiazepine (glejte poglavji 4.2 in 4.4).
How to use Busulfan Fresenius Kabi 
Kako uporabljati zdravilo Busulfan Fresenius Kabi
Skin: rash, itching, loss of hairs. 
Koža: izpuščaj, srbenje, izpadanje las.
Renal disorder 
Razredčena raztopina
Calculation of the quantity of Busulfan Fresenius Kabi to be diluted and of the diluent Busulfan Fresenius Kabi must be diluted prior to use with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%. 
Izračun količine zdravila Busulfan Fresenius Kabi, ki ga morate razredčiti, in tekočine za redčenje Zdravilo Busulfan Fresenius Kabi je potrebno pred uporabo razredčiti z 0,9 % raztopino natrijevega klorida za injiciranje (9 mg/ml) ali s 5 % raztopino glukoze za injiciranje.
As with other cytotoxic compounds, caution should be exercised in handling and preparing the busulfan solution: - The use of gloves and protective clothing is recommended. 
Kot pri vseh citotoksičnih spojinah, morate biti pri ravnanju z busulfanom in pri njegovi pripravi previdni:
Obese patients 
Debeli bolniki
In this case infusion sets with minimal priming space should be used (i.e 0.3-0.6 ml), primed with medicinal product solution prior to beginning the actual busulfan infusion and then flushed with sodium chloride 9 mg/ml (0.9%) solution for injection or glucose (5%) solution for injection. 
V tem primeru je treba uporabiti komplete za infundiranje z najmanjšim možnim volumnom za izpiranje (tj. 0,3-0,6 ml), pri katerih najprej sistem splaknemo z majhno količino busulfana pred dejanskim infundiranjem busulfana (izpiranje), in nato po končanem infundiranju sistem splaknemo z 0,9 % raztopino natrijevega klorida za injiciranje (9 mg/ml) ali s 5 % raztopino glukoze za injiciranje.
There is no known antidote to busulfan other than haematopoietic progenitor cell transplantation. 
Razen transplantacije hematopoetskih progenitorskih celic ni znanega antidota za busulfan.
Busulfan Fresenius Kabi must be prepared by a healthcare professional using sterile transfer techniques. 
Zdravilo Busulfan Fresenius Kabi mora pripraviti usposobljen zdravstveni delavec/delavka v sterilnih pogojih.
After dilution, 1 ml of solution for infusion contains 0.5 mg of busulfan. 
Po redčenju 1 ml raztopine za infundiranje vsebuje 0,5 mg busulfana.
No interaction was observed when busulfan was combined with fluconazole (antifungal agent). 
Pri zdravljenju s kombinacijo busulfana in flukonazola (antimikotik) niso ugotovili medsebojnega delovanja.
Hepatic veno-occlusive disease is a major complication that can occur during treatment with busulfan. 
Poglavitni zaplet, ki se lahko pojavi med zdravljenjem z busulfanom, je veno-okluzivna bolezen jeter.
Busulfan Fresenius Kabi must be diluted prior to administration. 
Zdravilo Busulfan Fresenius Kabi je potrebno pred uporabo razredčiti.
Headache Nervous system disorders [Not Elsewhere Classified] 
Bolezni živčevja glavobol, bolezni živčevja [nerazvrščene možganska krvavitev, encefalopatija drugje]
This medicine contains the active substance busulfan, which belongs to a group of medicines called alkylating agents. 
Kaj je zdravilo Busulfan Fresenius Kabi in za kaj ga uporabljamo To zdravilo vsebuje aktivno učinkovino busulfan, ki spada v skupino zdravil, imenovanih alkilirajoče učinkovine.
Periodic monitoring of renal function should be considered during therapy with busulfan (see section 
Med terapijo z busulfanom je potreben občasen nadzor ledvične funkcije (glejte poglavje 4.8).
Liver disorders. 
Bolezni jeter.
Therefore, men treated with busulfan are advised not to father a child during and up to 6 months after treatment and to seek advice on cryo-conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with busulfan. 
Priporočljivo je, da se moški pred zdravljenjem z busulfanom posvetujejo glede shranitve semena z zamrznitvijo, saj zaradi zdravljenja obstaja možnost trajne neplodnosti.
Hypoalbuminaemia Electrolyte disturbance Hyperglycaemia 
Presnovne in prehranske motnje hipoalbuminemija, motnje elektrolitov, hiperglikemija anoreksija
Busulfan Fresenius Kabi must not be put into an intravenous bag that does not contain sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%. 
Zdravila Busulfan Fresenius Kabi ne smete dati v intravensko vrečko, v kateri ni 0,9 % raztopine natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopine glukoze za injiciranje.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Busulfan Fresenius Kabi 6 mg/ml sterile concentrate busulfan 
IME ZDRAVILA IN POT(I) UPORABE Busulfan Fresenius Kabi 6 mg/ml sterilen koncentrat busulfan intravenska uporaba po redčenju
PROCEDURE FOR PROPER DISPOSAL 
PRIPOROČILA ZA VARNO RAVNANJE
A reduced incidence of Hepatic Veno Occlusive Disease (HVOD) and other regimen-related toxicity have been observed in patients when the lag time between the last dose of oral busulfan and the first dose of cyclophosphamide is > 24hours. 
Pri bolnikih, kjer je bil čas zakasnitve med zadnjim peroralnim odmerkom busulfana in prvim odmerkom ciklofosfamida večji 24 ur, so opazili zmanjšano pojavnost veno-okluzivne bolezni jeter (Hepatic VenoOcclusive Disease - HVOD) in drugih toksičnosti, povezanih z njuno uporabo.
Infections and infestations 
Infekcijske in parazitske bolezni:
NAME OF THE MEDICINAL PRODUCT Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion 
IME ZDRAVILA Busulfan Fresenius Kabi 6 mg/ml koncentrat za raztopino za infundiranje
METHOD AND ROUTE OF ADMINISTRATION Read the package leaflet before use Intravenous use after dilution. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Pred uporabo preberite priloženo navodilo!
Diluted Busulfan Fresenius Kabi is a clear colourless solution. 
Razredčeno zdravilo Busulfan Fresenius Kabi je prozorna, brezbarvna raztopina.
Busulfan Fresenius Kabi in combination with fludarabine The recommended dose of busulfan is 3.2 mg/kg Each infusion will last 3 hours 
Zdravilo Busulfan Fresenius Kabi v kombinaciji s fludarabinom - Priporočeni odmerek zdravila Busulfan Fresenius Kabi je 3,2 mg/kg.
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion busulfan 
Busulfan Fresenius Kabi 6 mg/ml koncentrat za raztopino za infundiranje busulfan
• Quantity of diluent: (A ml Busulfan Fresenius Kabi) x (10) = B ml of diluent To prepare the final solution for infusion, add (A) ml of Busulfan Fresenius Kabi to (B) ml of diluent 
• Količina redčila: (A ml zdravila Busulfan Fresenius Kabi) x (10) = B ml redčila Za pripravo končne raztopine za infundiranje dodajte (A) ml zdravila Busulfan Fresenius Kabi v (B) ml redčila (0,9 % raztopina natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopina glukoze za injiciranje).
STATEMENT OF ACTIVE SUBSTANCE One ml of concentrate contains 6 mg of busulfan and provides 0.5 mg/ml of busulfan after dilution 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN En ml koncentrata vsebuje 6 mg busulfana, po redčenju je koncentracija busulfana 0,5 mg/ml.
The median time to neutropenia was 4 days for both autologous and allogeneic patients. 
Pri avtolognih in alogenskih bolnikih je bil mediani čas do nevtropenije 4 dni.
Femoral artery thrombosis Capillary leak 
Žilne bolezni hipertenzija hipotenzija tromboza vazodilacija femoralna arterijska tromboza sindrom kapilarnega prepuščanja
Immune system disorders 
Bolezni imunskega sistema: